Combining Topical Imiquimod With Local Radiotherapy for Treatment of Mycosis Fungoides
Status:
Not yet recruiting
Trial end date:
2026-02-01
Target enrollment:
Participant gender:
Summary
Mycosis fungoides (MF) is the most common subtype of cutaneous T cell lymphoma (MF) and
presents as cutaneous patches, plaques, and tumors. Radiation therapy (RT) is a frequently
pursued management option for CTCL, especially in patients with more advanced skin disease.
Imiquimod stimulates a Th1 lymphocyte response with increased IL-2 and IFN-α, but also
induces IFN-α, TNF-α, IL-1α, IL-6, and IL-8, thereby bridging both innate and adaptive
immunity. Dosing of both radiotherapy (RT) and imiquimod are based on standard-of-care
doses/frequencies for CTCL. The reason imiquimod topical is given for a week before giving RT
is to prime innate immune activity for when RT is delivered. It is believed that this serves
as an adjuvant for the CD8+ antitumor response generated by RT. The primary aim of this study
is to assess the safety and efficacy of a combination local radiotherapy and topical
imiquimod approach for the treatment of conventional (CD4+) MF.